BIODESIX INC Business Finance Contracts & Agreements
37 Contracts & Agreements
- Assignment Agreements (2 contracts)
- Credit Agreements (5)
- Investor Rights Agreements (1)
- Loan Agreements (7)
- Note Agreements (1)
- Purchase Agreements (5)
- Registration Rights Agreements (4)
- Stock Agreements (7)
- Subscription Agreements (1)
- Underwriting Agreements (3)
- Warrant Agreements (1)
- Registration Rights Agreement, dated as of April 5, 2024 between Biodesix, Inc. and the Investors (Filed With SEC on April 9, 2024)
- Securities Purchase Agreement, dated as of April 5, 2024 between Biodesix, Inc. and certain members of management, certain of its directors and funds affiliated with those... (Filed With SEC on April 9, 2024)
- Securities Purchase Agreement, dated as of April 5, 2024 between Biodesix, Inc. and certain of the Investors (Filed With SEC on April 9, 2024)
- Underwriting Agreement, dated April 5, 2024, by and among Biodesix, Inc. and TD Securities (USA) LLC, William Blair & Company, L.L.C. and Canaccord Genuity LLC (Filed With SEC on April 9, 2024)
- Third Amendment to Credit Agreement and Guaranty, dated February 29, 2024, by and among the Company and Perceptive Credit Holdings IV, LP (Filed With SEC on March 1, 2024)
- Limited Waiver, dated February 14, 2024, by and between Biodesix, Inc. and Perceptive Credit Holdings IV, LP (Filed With SEC on March 1, 2024)
- Form of Subscription Agreement, dated August 3, 2023 (Filed With SEC on August 7, 2023)
- Limited Waiver, dated April 7, 2023, by and between Biodesix, Inc. and Perceptive Credit Holdings IV, LP (Filed With SEC on May 11, 2023)
- Warrant to Purchase Stock, dated May 10, 2023, issued by the Company to Perceptive Credit Holdings IV, LP (Filed With SEC on May 11, 2023)
- Warrant to Purchase Stock, dated November 21, 2022, issued by the Company to Perceptive Credit Holdings IV, LP (Filed With SEC on November 21, 2022)
- Underwriting Agreement, dated November 16, 2022, between Biodesix, Inc. and William Blair & Company, L.L.C (Filed With SEC on November 21, 2022)
- Consent and Fourth Amendment to Loan and Security Agreement (Filed With SEC on November 3, 2022)
- Consent and Third Amendment to Loan and Security Agreement (Filed With SEC on April 11, 2022)
- Subscription Agreement without registration rights, entered by the three members of our Board of Directors, dated April 7, 2022 (Filed With SEC on April 11, 2022)
- Subscription Agreement with resale registration rights provision, dated April 7, 2022 (Filed With SEC on April 11, 2022)
- Registration Rights Agreement, dated March 7, 2022, by and between Biodesix, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on March 7, 2022)
- Purchase Agreement, dated March 7, 2022, by and between Biodesix, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on March 7, 2022)
- Consent and Second Amendment to Loan and Security Agreement (Filed With SEC on January 4, 2022)
- Consent and First Amendment to Loan and Security Agreement (Filed With SEC on November 15, 2021)
- Loan and Security Agreement, dated March 19, 2021 (Filed With SEC on March 23, 2021)
- Biodesix, Inc. 2020 Employee Stock Purchase Plan (Filed With SEC on October 26, 2020)
- Specimen stock certificate evidencing shares of Common Stock (Filed With SEC on October 21, 2020)
- Form of Underwriting Agreement (Filed With SEC on October 21, 2020)
- IP Assignment Agreement between Oncimmune Limited, and Biodesix, Inc., dated October 31, 2019 (Filed With SEC on October 9, 2020)
- Loan and Security Agreement, by and among Innovatus Life Sciences Lending Fund I, LP, the Lenders listed therein, and Biodesix, Inc., dated February 23, 2018 (Filed With SEC on October 9, 2020)
- Form of Stock Option Grant Notice under the Biodesix, Inc. Bonus-To-Options Program (Filed With SEC on October 9, 2020)
- Form of Notice of Exercise under the Amended and Restated 2006 Employee, Director and Consultant Stock Plan (Filed With SEC on October 9, 2020)
- Form of Option Agreement under the Amended and Restated 2006 Employee, Director and Consultant Stock Plan (Filed With SEC on October 9, 2020)
- Form of Stock Option Grant Notice under the Amended and Restated 2006 Employee, Director and Consultant Stock Plan (Filed With SEC on October 9, 2020)
- Biodesix, Inc. Amended and Restated 2006 Employee, Director and Consultant Stock Plan, as amended to date (Filed With SEC on October 9, 2020)
- Asset Purchase Agreement between Oncimmune Limited and Biodesix, Inc., dated June 27, 2019, as amended to date (Filed With SEC on October 2, 2020)
- Asset Purchase Agreement among Biodesix, Inc., Integrated Diagnostics, Inc., and the stockholders of Integrated Diagnostics, Inc., listed therein, dated June 30, 2018 (Filed With SEC on October 2, 2020)
- Patent Assignment between Biodesix, Inc., and Integrated Diagnostics, Inc., dated June 30, 2018 (Filed With SEC on October 2, 2020)
- Limited Consent Agreement and Second Amendment to Loan and Security Agreement, by and among Innovatus Life Sciences Lending Fund I, LP, the Lenders listed therein, and Biodesix,... (Filed With SEC on October 2, 2020)
- Secured Promissory Note held by Innovatus Life Sciences Lending Fund I, LP, in Biodesix, Inc., dated February 23, 2018 (Filed With SEC on October 2, 2020)
- Warrant held by Innovatus Life Sciences Lending Fund I, LP, to Purchase Series G Preferred Stock, dated February 23, 3018 (Filed With SEC on October 2, 2020)
- Eleventh Amended and Restated Investor Rights Agreement, by and among Biodesix, Inc. and the investors listed on Exhibit A thereto, dated October 10, 2018 (Filed With SEC on October 2, 2020)
